SynthesisBMC infectious diseases2016
How severe and prevalent are Ebola and Marburg viruses? A systematic review and meta-analysis of the case fatality rates and seroprevalence.
Synthesis in BMC infectious diseases, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
43 citing papers in PubMed, 5 syntheses or guidelines pooled it, 74 citations in OpenAlex.
- A century of emergence: trends and patterns in human viral pathogens, 1900-2024, a systematic review.BMC infectious diseases · 2025Pooled it
- Marburg virus disease outbreaks, mathematical models, and disease parameters: a systematic review.The Lancet. Infectious diseases · 2024Pooled it
- Ebola virus disease in pregnancy: a systematic review and meta-analysis.Transactions of the Royal Society of Tropical Medicine and Hygiene · 2022Pooled it
- Estimating case fatality risk of severe Yellow Fever cases: systematic literature review and meta-analysis.BMC infectious diseases · 2021Pooled it
- Seroprevalence of severe fever with thrombocytopenia syndrome virus in China: A systematic review and meta-analysis.PloS one · 2017Pooled it
- Safety and Immunogenicity of a 2-Dose Heterologous Vaccination Regimen With Ad26.ZEBOV and MVA-BN-Filo Ebola Vaccines: 12-Month Data From a Phase 1 Randomized Clinical Trial in Uganda and Tanzania.The Journal of infectious diseases · 2019Trial
- Article
- Quarantine-associated viral pathogens in non-human primates: pathobiology, diagnostic surveillance, control strategies, and one health implications.Frontiers in veterinary science · 2026Review
- Development of a neutralization assay and bioluminescent imaging mouse model for Dehong virus (DEHV) using a pseudovirus system.Microbiology spectrum · 2025Article
- Review
- A public, cross-reactive glycoprotein epitope confounds Ebola virus serology.Journal of medical virology · 2024Article
- Ebola disease outbreak caused by the Sudan virus in Uganda, 2022: a descriptive epidemiological study.The Lancet. Global health · 2024Article
- Article
- A high-throughput, polymerase-targeted RT-PCR for broad detection of mammalian filoviruses.Microbiology spectrum · 2024Article
- Delayed treatment of cynomolgus macaques with a FVM04/CA45 monoclonal antibody cocktail provides complete protection against lethal Sudan virus infection.Journal of virology · 2024Article
- Prevalence of human filovirus infections in sub-Saharan Africa: A systematic review and meta-analysis protocol.Systematic reviews · 2024Article
- Translational success of fundamental virology: a VSV-vectored Ebola vaccine.Journal of virology · 2024Review
- A Review of the Interaction between miRNAs and Ebola Virus.International journal of molecular and cellular medicine · 2024Review
- A mathematical model of Marburg virus disease outbreaks and the potential role of vaccination in control.BMC medicine · 2023Article
- Pseudotyped Viruses for Marburgvirus and Ebolavirus.Advances in experimental medicine and biology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 5 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundEbola and Marburg virus diseases are said to occur at a low prevalence, but are very severe diseases with high lethalities. The fatality rates reported in different outbreaks ranged from 24-100%. In addition, sero-surveys conducted have shown different seropositivity for both Ebola and Marburg viruses. We aimed to use a meta-analysis approach to estimate the case fatality and seroprevalence rates of these filoviruses, providing vital information for epidemic response and preparedness in countries affected by these diseases.
methodsPublished literature was retrieved through a search of databases. Articles were included if they reported number of deaths, cases, and seropositivity. We further cross-referenced with ministries of health, WHO and CDC databases. The effect size was proportion represented by case fatality rate (CFR) and seroprevalence. Analysis was done using the metaprop command in STATA.
resultsThe weighted average CFR of Ebola virus disease was estimated to be 65.0% [95% CI (54.0-76.0%), I
conclusionsThe pooled CFR and seroprevalence for Ebola and Marburg viruses were found to be lower than usually reported, with species differences despite high heterogeneity between studies. Countries with an improved health surveillance and epidemic response have lower CFR, thereby indicating need for improving early detection and epidemic response in filovirus outbreaks.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.